Repligen (NASDAQ:RGEN) Reaches New 52-Week High - Time to Buy?

Repligen Corporation (NASDAQ:RGEN - Get Free Report)'s share price reached a new 52-week high on Tuesday. The stock traded as high as $198.87 and last traded at $194.09, with a volume of 1567144 shares changing hands. The stock had previously closed at $189.68.

Analysts Set New Price Targets

A number of equities research analysts recently commented on RGEN shares. Zacks Research upgraded shares of Repligen from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 30th. UBS Group upped their target price on shares of Repligen from $195.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. HSBC lowered their target price on Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Benchmark upgraded Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Finally, Evercore reaffirmed an "outperform" rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $168.57.

Repligen Price Performance

The company's fifty day moving average is $166.40 and its 200 day moving average is $139.51. The firm has a market cap of $10.95 billion, a price-to-earnings ratio of 265.88, a PEG ratio of 3.46 and a beta of 1.05. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the business earned $0.26 EPS. The company's revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts predict that Repligen Corporation will post 2.06 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RGEN. United Capital Financial Advisors LLC acquired a new position in shares of Repligen during the 2nd quarter worth approximately $380,756,000. Wasatch Advisors LP boosted its holdings in shares of Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after buying an additional 346,720 shares during the last quarter. Maverick Capital Ltd. bought a new position in shares of Repligen in the first quarter valued at $178,946,000. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 3.8% in the first quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company's stock valued at $129,341,000 after buying an additional 39,808 shares in the last quarter. Finally, Fred Alger Management LLC increased its holdings in Repligen by 154.3% during the fourth quarter. Fred Alger Management LLC now owns 911,527 shares of the biotechnology company's stock worth $149,363,000 after buying an additional 553,105 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.